This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. First PI3k inhibitor launches into crowded hematology markets. Nat Biotechnol 32, 963–964 (2014). https://doi.org/10.1038/nbt1014-963
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1014-963
This article is cited by
-
Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors
Cancer Chemotherapy and Pharmacology (2019)